CHARVI KHURANA: Open Payments
NPI 1780257097 · NEW ORLEANS, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$845 in 19 payments from 9 companies in 2025. Trend: 2023 $310 · 2024 $236 · 2025 $845
Food & beverage: $845
| Company | Payments | Amount |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $158 |
| Exact Sciences Corporation | 2 | $149 |
| Janssen Scientific Affairs, LLC | 1 | $139 |
| Ipsen Biopharmaceuticals, Inc | 1 | $125 |
| GENZYME CORPORATION | 1 | $125 |
| ABBVIE INC. | 3 | $58 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 2 | $48 |
| QOL Medical, LLC | 1 | $21 |
| Ardelyx, Inc. | 1 | $21 |
Products named: ENTYVIO, The Cologuard Plus Collection Kit, IQIRVO, DUPIXENT, XIFAXAN, LINZESS, Sucraid, SKYRIZI.
Industry payments across LA — which companies pay providers there.
